Andres
Iñiguez Romo
![Foto de Andres](/img/nophoto.png)
![Foto de University of Amsterdam](/img/noimage_org.png)
University of Amsterdam
Ámsterdam, HolandaPublicacións en colaboración con investigadores/as de University of Amsterdam (22)
2022
2021
-
Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets
The Lancet, Vol. 397, Núm. 10270, pp. 199-207
2020
-
Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study
Atherosclerosis, Vol. 295, pp. 45-53
-
Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries
American Heart Journal, Vol. 220, pp. 108-115
-
Bioresorbable scaffolds versus everolimus-eluting metallic stents: Five-year clinical outcomes of the randomised ABSORB II trial
EuroIntervention, Vol. 16, Núm. 11, pp. E938-E941
-
Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries
American Journal of Cardiovascular Drugs, Vol. 20, Núm. 3, pp. 259-269
-
Endothelial shear stress and vascular remodeling in bioresorbable scaffold and metallic stent
Atherosclerosis, Vol. 312, pp. 79-89
-
Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction
Revista espanola de cardiologia (English ed.), Vol. 73, Núm. 2, pp. 114-122
-
Incidence, predictors and prognostic impact of intracranial bleeding within the first year after an acute coronary syndrome in patients treated with percutaneous coronary intervention
European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 7, pp. 764-770
-
P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects
European heart journal. Cardiovascular pharmacotherapy, Vol. 6, Núm. 1, pp. 31-42
2019
-
Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study
American Heart Journal, Vol. 209, pp. 97-105
-
Three-year clinical outcomes after dual-therapy COMBO stent placement: Insights from the REMEDEE registry
Catheterization and Cardiovascular Interventions, Vol. 94, Núm. 3, pp. 342-347
2018
-
1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration
JACC: Cardiovascular Interventions, Vol. 11, Núm. 19, pp. 1969-1978
-
Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score
International Journal of Cardiology, Vol. 254, pp. 10-15
-
First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial
EuroIntervention
-
Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy
EuroIntervention, Vol. 14, Núm. 5, pp. e570-e579
2017
-
Comparison of everolimus-eluting bioresorbable scaffolds with everolimuseluting metallic stents for treatment of coronary artery stenosis: Three-year follow-up of the ABSORB II randomized trial
Bioresorbable Scaffolds: From Basic Concept to Clinical Applications (CRC Press), pp. 224-237
-
One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent
International Journal of Cardiology, Vol. 226, pp. 60-64
-
Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry
Open Heart, Vol. 4, Núm. 2
2016
-
1-Year Results of the REMEDEE Registry: Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered (Combo) Stent in a Multicenter, Prospective All-Comers Registry
JACC: Cardiovascular Interventions, Vol. 9, Núm. 11, pp. 1127-1134